4.8 Article

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial

Journal

LANCET
Volume 377, Issue 9775, Pages 1409-1420

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(11)60404-2

Keywords

-

Funding

  1. Sanofi-Aventis
  2. Bristol-Myers Squibb
  3. Medtronic
  4. GlaxoSmithKline
  5. AstraZeneca
  6. Population Health Research Institute
  7. Eli Lilly
  8. Novartis
  9. AstraZenca
  10. Merck
  11. Boehringer Ingelheim
  12. Hamilton Health Sciences
  13. Servier
  14. Astellas
  15. Bayer
  16. Daiichi-Sankyo-Lilly
  17. Otsuka
  18. Roche
  19. Medicines Company
  20. Terumo Medical
  21. Canadian Network for Trials Internationally (CANNeCTIN), an initiative of the Canadian Institutes of Health Research

Ask authors/readers for more resources

Background Small trials have suggested that radial vascular complications and bleeding compared with superior to femoral access in patients with acute angiography with possible intervention. access for percutaneous coronary intervention (PCI) reduces femoral access. We aimed to assess whether radial access was coronary syndromes (ACS) who were undergoing coronary Methods The RadIal Vs femorAL access for coronary intervention (RIVAL) trial was a randomised, parallel group, multicentre trial. Patients with ACS were randomly assigned (1:1) by a 24 h computerised central automated voice response system to radial or femoral artery access. The primary outcome was a composite of death, myocardial infarction, stroke, or non-coronary artery bypass graft (non-CABG)-related major bleeding at 30 days. Key secondary outcomes were death, myocardial infarction, or stroke; and non-CABG-related major bleeding at 30 days. A masked central committee adjudicated the primary outcome, components of the primary outcome, and stent thrombosis. All other outcomes were as reported by the investigators. Patients and investigators were not masked to treatment allocation. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, NCT01014273. Findings Between June 6, 2006, and Nov 3, 2010, 7021 patients were enrolled from 158 hospitals in 32 countries. 3507 patients were randomly assigned to radial access and 3514 to femoral access. The primary outcome occurred in 128 (3.7%) of 3507 patients in the radial access group compared with 139 (4.0%) of 3514 in the femoral access group (hazard ratio [HR] 0.92, 95% CI 0.72-1.17; p=0.50). Of the six prespecified subgroups, there was a significant interaction for the primary outcome with benefit for radial access in highest tertile volume radial centres (HR 0.49, 95% CI 0.28-0.87; p=0.015) and in patients with ST-segment elevation myocardial infarction (0.60, 0.38-0.94; p=0.026). The rate of death, myocardial infarction, or stroke at 30 days was 112 (3.2%) of 3507 patients in the radial group compared with 114 (3.2%) of 3514 in the femoral group (HR 0.98, 95% CI 0.76-1.28; p=0 90). The rate of non-CABG-related major bleeding at 30 days was 24 (0.7%) of 3507 patients in the radial group compared with 33 (0.9%) of 3514 patients in the femoral group (HR 0.73, 95% CI 0.43-1.23; p=0. 23). At 30 days, 42 of 3507 patients in the radial group had large haematoma compared with 106 of 3514 in the femoral group (HR 0.40, 95% CI 0-28-0.57; p<0.0001). Pseudoaneurysm needing closure occurred in seven of 3507 patients in the radial group compared with 23 of 3514 in the femoral group (HR 0.30, 95% CI 0.13-0.71; p=0. 006). Interpretation Radial and femoral approaches are both safe and effective for PCI. However, the lower rate of local vascular complications may be a reason to use the radial approach.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available